Navigation Links
HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
Date:6/12/2008

Rheumatoid Arthritis is the Leading Cause of Work Disability in Europe

PARIS, June 13 /PRNewswire-FirstCall/ -- New data announced today showed that treating patients with early, active rheumatoid arthritis (RA) with Abbott's HUMIRA(R) (adalimumab) and methotrexate (MTX) resulted in an indirect cost savings of euro 4,845 (or approximately USD$6,086 using exchange rates at the time of the study) per patient per year compared to MTX treatment alone. These cost savings were attributed to improved work performance, ability to gain or regain employment and a reduction in the number of missed workdays. A separate analysis found that joint damage in the early stages of RA is a predictor of a patient's ability to gain or retain employment. These data were presented at the European League Against Rheumatism (EULAR) annual meeting in Paris.

"While rheumatoid arthritis is a progressive and chronic disease, patients may be able to continue productive work lives with the help of treatment options such as adalimumab," said Ronald F. van Vollenhoven, M.D., Ph.D., Karolinska University Hospital, Stockholm, Sweden.

More than five million people worldwide have RA, and most of them are considered to be in the prime of their working lives (between 30-50 years of age). The data are from DE032, an economic companion study to PREMIER, a two-year, randomized, double-blind, comparator-controlled study that compared the effectiveness of HUMIRA and MTX to MTX alone in treating early RA. At baseline, a total of 433 patients with early, active RA were identified, including 235 active, paid workers. Patients were evaluated on three measures: number of missed days of work due to RA, degree of work performance affected by RA and employment status.

The study found that:

-- For paid and household workers, estimated indirect cost savings in

patients with early RA treated with HUMIRA plus MTX (compared to MTX

alone) were euro 4,845 (or
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
2. Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
3. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
4. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
5. Data Show that Abbotts HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
6. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
7. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
8. Treating diabetes during pregnancy can break link to childhood obesity
9. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
10. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
11. Family-based treatment more effective than supportive psychotherapy in treating bulimia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... the secrets to better treating the pernicious disorders of ... a paper from American University,s Center for Behavioral Neuroscience. ... obesity with therapies aimed at areas of the brain ... on the hippocampus could play a role in reducing ... therapies and preventive measures often fall short. This is ...
(Date:7/23/2014)... 23, 2014 (HealthDay News) --,Jealousy may not be the ... can get downright possessive when it comes to the ... affection toward what was actually a stuffed dog, the ... pushing the stuffed dog aside, report researchers from the ... streak only surfaced when owners were attending to the ...
(Date:7/23/2014)... research on human cancer genes have been focused on ... to be translated in the form of amino acids ... a regulatory region or activator which controls the expression ... little was known of the role exerted such DNA ... today in Nature in collaboration with the ...
(Date:7/23/2014)... County, NJ (PRWEB) July 23, 2014 ... is the first hospital in New Jersey to receive ... most advanced robotics platform in the da Vinci series. ... and a profound step forward in innovation. The intuitive ... used across a wide spectrum of minimally invasive and ...
(Date:7/23/2014)... Vancouver, BC (PRWEB) July 23, 2014 ... has recently announced the launch of its custom orthotics ... correcting and eliminating foot abnormalities in order to restore ... the joints and cause less fatigue and pain. In ... and reduced pressure in the foot, resulting in relief ...
Breaking Medicine News(10 mins):Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:Dogs Can Get Jealous, Too 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4Health News:Custom Orthotics at Burnaby PhysioCare Now Correct Foot Abnormalities 2
... risk of obesity later in life, research suggests , ... during pregnancy reduces an infant,s birth weight, which may ... researchers say. , In a new study, 84 first-time ... groups, with those in the exercise group participating in ...
... ... Laboratory Notebook) to be fully supported on the revolutionary Apple iPad. , ... (PRWEB) April 5, 2010 -- Amphora Research ... supported on the revolutionary Apple iPad., , ,"Science often happens in places where using a ...
... ... today. This newly launched initiative from MedPage Today, the online daily breaking medical news ... and critical thinkers while preserving their editorial independence. , ... Little Falls, New Jersey (PRWEB) April 5, 2010 ...
... finds relationships often founder after failed pregnancy, , MONDAY, April ... when she miscarried at 14 weeks. That she was already ... understand was that having my other children and realizing how ... who lives in Highland Ranch, Colo. , At first, her ...
... ... Day on April 7th, Swanson Health Products will donate five percent of the day,s sales ... ... Health Products plans to donate five percent of sales from Wednesday, April 7th, to Vitamin ...
... ... Expanded Its Free Webinars to Cover New Obama Health Reform ... Insurance Reimbursement Checks Directly with Valid Assignment and Nondiscrimination Protections ... and Individual Health Plan to Accept Patient Assignment to Send ...
Cached Medicine News:Health News:Expectant Mom's Exercise Keeps Newborn's Birth Weight Down 2Health News:Amphora's PatentSafe Electronic Laboratory Notebook Fully Supported on the Apple iPad 2Health News:MedPage Today Launches New Related SitesTM Initiative with KevinMD.com as First Collaborator 2Health News:MedPage Today Launches New Related SitesTM Initiative with KevinMD.com as First Collaborator 3Health News:For Many Couples, Toll of Miscarriage Lingers 2Health News:For Many Couples, Toll of Miscarriage Lingers 3Health News:For Many Couples, Toll of Miscarriage Lingers 4Health News:Swanson Health Products to Make Donation for Haiti Relief Efforts 2Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 2Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 3Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 4Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 5
(Date:7/23/2014)... LONDON , July 23, 2014  Lightlake ... developing addiction treatments based on its expertise in ... an investigational new drug application ("IND") with respect ... Lightlake also announced today that it has received ... Drug Abuse ("NIDA"), part of the National Institutes ...
(Date:7/23/2014)... , July 23, 2014  Silk Road ... the transcarotid treatment of intra- and extra-cranial cerebrovascular ... P. Wallace to the position of Chief ... lead the company,s Research and Development efforts across ... Prior to joining Silk Road ...
(Date:7/23/2014)... , July 23, 2014  ACON Equity Partners III, ... Investments, L.L.C. ("ACON") announced it has completed the purchase ... from Audax Group and Parthenon Capital Partners. IWP is ... billion Workers, Compensation, Automobile Personal Injury Protection and Personal ... . As part of this ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3ACON Investments Acquires Injured Workers Pharmacy 2ACON Investments Acquires Injured Workers Pharmacy 3
... Therapeutics, Inc. (Nasdaq: ECTE ), a company ... wireless, transdermal continuous glucose monitoring system and its Prelude® ... results for the year ended December 31, 2011.  Echo,s ... website at www.echotx.com . 2011 ...
...   Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... of senior vice president and chief commercial officer. Mr. Palekar ... activities. "Rohan has an outstanding track record of ... president and CEO of Avanir. "I am delighted that we ...
Cached Medicine Technology:Echo Therapeutics, Inc. Announces 2011 Financial Results 2Echo Therapeutics, Inc. Announces 2011 Financial Results 3Echo Therapeutics, Inc. Announces 2011 Financial Results 4Echo Therapeutics, Inc. Announces 2011 Financial Results 5Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer 2Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer 3
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: